Contributors

Contributors Recent News

Bittensor Backer Sees Its TAO Token Topping $62,500 In 2030 From $400s Today
Bittensor's decentralized AI model may be the best-kept secret in crypto—and one venture capitalist believes it could 135x from today's price
|
Why Spotify Stock Rose As Much As 3.9% After 10:10 AM On May 12
Find out why Spotify Technology shares rose as much as 3.9% after 10:10 AM on May 12 - a move driven by a signal many traders view as a crucial indicator.
|
How Much Inventory Did Companies Actually Build Ahead Of Tariffs?
Award-winning Author Sam Ro discusses the inventory buildup of companies ahead of tariffs - and why it matters...
|
Deploy Cash And Reduce Hedges, Peak Tariff Uncertainty Is Over But Peak Economic Uncertainty Is Not
|
Profiting From A Pharma Panic
How President Trump's executive order could unlock asymmetric upside for us.
|
Risk-Off Mode Could Spur Further Yen Decline
|
Money Laundering: Understanding The 3 Key Stages
Money laundering is a complex crime with three key stages: placement, layering, and integration. Stay informed to protect yourself.
|
How To Trade SPY And Top Tech Stocks, As Tentative China-US Pact Lifts Global Gloom
How to trade the SPY and top tech stocks using technical analysis, as tentative U.S-China pact lifts global gloom.
|
The Race To Go Public Among New Gen Chinese 'AI Tigers'
New Chinese AI startups try to steer clear of controversy, reduce overreliance on state support, while also providing strong growth potential.
|
UX on a Budget: How Startups Can Build Better UX Without Breaking the Bank
Every $1 invested in user experience (UX) design returns up to $100 and it is possible to build an affordable UX.
|
SPDR Gold Trust Shares Rise After Key Trading Signal
A significant trading signal occurred for SPDR Gold Trust shares, at $306.16, after which GLD rose up to 0.8%.
|
CMB.TECH CEO Speaks On Shifting Investor Focus From Asset Values To Sustainable Earnings Power
|
Hopium Buying - India Ready To Cut Tariffs to 4%, Trump Floats China Tariffs At 80%, UK Not A Model
|
New FDA Leadership Could Raise The Bar For Drug Approvals
A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.
|
Here's Why Robots Struggle With Real-time Adaptability
The walled gardens of major robotics firms have slowed collaborative breakthroughs.
|
VIRTUAL Is Surging Again. Can Crypto's Agentic AI Mashup Sustain Its Momentum?
By democratizing access to AI agents, Virtuals Protocol is sparking new use cases and trading opportunities.
|
BOE Cuts Interest Rates As UK Confronts Economic Doubt, Election 'Revolution'
|
Fosun International Sheds Real Estate Assets In Portugal
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved